BioGend Therapeutics Co., Ltd. (6733)

Overview

BioGend Therapeutics Co., Ltd. is a pioneering company based in Taipei, Taiwan, specializing in the development of regenerative bio-orthopaedic products since its inception in 2016. The firm is at the forefront of research and development in the field of orthobiologics, focusing on creating innovative solutions for bone and cartilage repair. By leveraging the potential of regenerative medicine, BioGend Therapeutics aims to address some of the most pressing needs in orthopaedic and reconstructive surgery.

Products and Services

• BiG-001 and BiG-006

These osteoinductive bone graft substitutes represent BioGend Therapeutics' commitment to advancing bone regenerative solutions. BiG-001 and BiG-006 are designed to foster bone growth and repair, catering to patients requiring bone grafts due to injuries, surgeries, or diseases. Their innovative formulation is a testament to the company's expertise in combining medical research with practical applications, potentially reducing recovery times and improving surgical outcomes for patients.

• BiG-009

The BiG-009 autologous cartilage repair system showcases BioGend Therapeutics' pioneering work in the regeneration of cartilage. This self-derived therapy is aimed at patients suffering from cartilage damage, offering a personalized approach to cartilage repair. By developing a system that utilizes the patient's own cells, BiG-009 stands out as a cutting-edge solution in the realm of orthobiologics, offering new hope for individuals facing joint disorders and injuries.